54f66d7c-b022-4df2-830d-48d55791c80e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.400
- KRAS_SIGNALING_DN+0.300
- MYC_TARGETS_V2+0.300
- PANCREAS_BETA_CELLS+0.300
- MYOGENESIS+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
- SPERMATOGENESIS+0.200
- ALLOGRAFT_REJECTION+0.100
- APICAL_SURFACE+0.100
Top 10 suppressed
- PROTEIN_SECRETION-0.600
- UV_RESPONSE_DN-0.500
- ANDROGEN_RESPONSE-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- TGF_BETA_SIGNALING-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- ANGIOGENESIS-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- HEDGEHOG_SIGNALING-0.300
- HEME_METABOLISM-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-94-7033-01A-11R-1949-07 | — | cohortSQ1 | 0.868 |
| 2 | TCGA-GD-A6C6-01A-21R-A31N-07 | — | — | 0.844 |
| 3 | TCGA-E9-A3HO-01A-11R-A213-07 | — | B | 0.823 |
| 4 | BS_TNRHHYNC | EPN | EPN Tumor | 0.814 |
| 5 | TCGA-GC-A6I3-01A-11R-A31N-07 | — | — | 0.802 |
| 6 | R175 | — | — | 0.801 |
| 7 | R64 | — | — | 0.785 |
| 8 | TCGA-AO-A1KR-01A-12R-A144-07 | — | E | 0.781 |
| 9 | TCGA-P3-A6SW-01A-11R-A34R-07 | — | — | 0.772 |
| 10 | SRR26320093 | — | — | 0.760 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |